Xiong Bo, Nie Dan, Cao Yin, Zou Yanke, Yao Yuanqing, Qian Jun, Rong Shunkang, Huang Jing
Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
Department of Gastroenterology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610500, China.
Heart Lung Circ. 2017 Nov;26(11):1200-1207. doi: 10.1016/j.hlc.2016.11.024. Epub 2017 Feb 13.
The effect of preoperative statin treatment (PST) on the risk of postoperative acute kidney injury (AKI) after cardiac surgery remains controversial. We performed a meta-analysis of randomised controlled trials (RCT) to investigate whether PST could improve the renal outcomes in patients undergoing cardiac surgery.
We conducted a comprehensive search on PubMed, Embase and Cochrane Central Register of Controlled Trials. Randomised controlled trials which reported incidence of AKI and renal replacement treatment (RRT), mean change of serum creatine (SCr) and C-reactive protein (CRP), length of stay in intensive care unit (LOS-ICU) and hospital (LOS-HOS) were included.
A total of nine RCTs, covering 3,201 patients were included. Based on the results of our meta-analysis, PST could not reduce the incidence of AKI (risk ratio (RR) 1.12, 95% confidence interval (CI) 0.97 to 1.29, p=0.37), and RRT (RR 1.13, 95% CI 0.45 to 2.85, p=0.80). Furthermore, SCr was not likely to be improved by PST (weighted mean difference (WMD) 0.03, 95% CI 0.00 to 0.06, p=0.055). However, the level of CRP (WMD -5.93, 95% CI 11.71 to 0.15, p=0.044) in patients treated with PST was significantly lower than that of patients administered with placebo. In addition, no significant difference was observed in LOS-ICU and LOS-HOS between PST and control groups.
Our meta-analysis suggests that PST cannot provide any benefit for improving renal complications and clinical outcomes, but may slightly reduce postoperative inflammation in patients undergoing cardiac surgery. In the future, more powerful RCTs will be needed to confirm these findings.
术前他汀类药物治疗(PST)对心脏手术后急性肾损伤(AKI)风险的影响仍存在争议。我们进行了一项随机对照试验(RCT)的荟萃分析,以研究PST是否能改善心脏手术患者的肾脏结局。
我们在PubMed、Embase和Cochrane对照试验中央注册库进行了全面检索。纳入报告了AKI发病率和肾脏替代治疗(RRT)、血清肌酐(SCr)和C反应蛋白(CRP)的平均变化、重症监护病房住院时间(LOS-ICU)和医院住院时间(LOS-HOS)的随机对照试验。
共纳入9项RCT,涵盖3201例患者。根据我们的荟萃分析结果,PST不能降低AKI的发病率(风险比(RR)1.12,95%置信区间(CI)0.97至1.29,p=0.37)和RRT(RR 1.13,95%CI 0.45至2.85,p=0.80)。此外,PST不太可能改善SCr(加权平均差(WMD)0.03,95%CI 0.00至0.06,p=0.055)。然而,接受PST治疗的患者的CRP水平(WMD -5.93,95%CI 11.71至0.15,p=0.044)显著低于接受安慰剂治疗的患者。此外,PST组和对照组在LOS-ICU和LOS-HOS方面未观察到显著差异。
我们的荟萃分析表明,PST对改善肾脏并发症和临床结局没有任何益处,但可能会略微减轻心脏手术患者的术后炎症。未来,需要更有力的RCT来证实这些发现。